Solid Biosciences (NASDAQ: TECH) and BIO-TECHNE (NASDAQ:TECH) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.


BIO-TECHNE pays an annual dividend of $1.28 per share and has a dividend yield of 0.7%. Solid Biosciences does not pay a dividend. BIO-TECHNE pays out 31.4% of its earnings in the form of a dividend.

Analyst Ratings

This is a summary of current ratings for Solid Biosciences and BIO-TECHNE, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Solid Biosciences 1 2 4 0 2.43
BIO-TECHNE 0 1 5 0 2.83

Solid Biosciences presently has a consensus price target of $45.14, indicating a potential upside of 0.88%. BIO-TECHNE has a consensus price target of $191.83, indicating a potential downside of 2.55%. Given Solid Biosciences’ higher probable upside, equities analysts plainly believe Solid Biosciences is more favorable than BIO-TECHNE.

Insider and Institutional Ownership

60.2% of Solid Biosciences shares are owned by institutional investors. Comparatively, 94.7% of BIO-TECHNE shares are owned by institutional investors. 3.4% of BIO-TECHNE shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.


This table compares Solid Biosciences and BIO-TECHNE’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Solid Biosciences N/A N/A N/A
BIO-TECHNE 19.50% 14.64% 9.53%

Valuation & Earnings

This table compares Solid Biosciences and BIO-TECHNE’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Solid Biosciences N/A N/A -$52.11 million ($2.88) -15.54
BIO-TECHNE $642.99 million 11.56 $126.15 million $4.07 48.37

BIO-TECHNE has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than BIO-TECHNE, indicating that it is currently the more affordable of the two stocks.


BIO-TECHNE beats Solid Biosciences on 12 of the 14 factors compared between the two stocks.

About Solid Biosciences

Solid Biosciences Inc. engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation. In addition, it is developing soft wearable assistive devices that have functional and therapeutic benefits to DMD patients. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.


Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, including cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment develops, manufactures, and sells tools, such as Biologics platform that enables researchers interrogate protein purity and identify contaminants during the development and production of biologics; Simple Western platform for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment offers controls and calibrators for hematology clinical instruments; blood chemistry and blood gas quality controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market; bulk purified proteins, enzymes, disease-state plasmas, infectious disease antigens, and processed serums to the clinical diagnostic industry; and Paratest, a novel and convenient stool collection and test device for the veterinary market. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with's FREE daily email newsletter.